Pereira M.P., Steinke S., Zeidler C. et al. EADV European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32 (7): 1059 1065.
Pereira M.P., Nau T. Zeidler C., Ständer S. Chronische Prurigo. Hautarzt 2018; 69 (4): 321 330.
Zeidler C., Ständer S. The pathogenesis of Prurigo nodularis ,Super-Itch‘ in exploration. Eur J Pain 2016; 20 (1): 37 40.
Raap U. Günther C. Pathogenese der Prurigo nodularis. Hautarzt. 2014; 65 (8): 691 696.
Whang K.A., Kang S., Kwatra S.G. Inpatient burden of prurigo nodularis in the United States. Medicines (Basel). 2019; 6 (3).
Iking A., Grundmann S., Chatzigeorgakidis E. et al. Prurigo as a symptom of atopic and nonatopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol 2013; 27 (5): 550 557.
Schneider G., Hockmann J., Stumpf A. Psychosomatic aspects of prurigo nodularis. Hautarzt 2014; 65 (8): 704 708.
Mettang T,Vonend A, Raap U Prurigo nodularis: its association with dermatoses and systemic disorders. Hautarzt 2014; 65 (8): 697 703.
Boozalis E., Tang O., Patel S. et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J. Am. Acad. Dermatol. 2018, 79, 714 719.
Wallace C.A., Sherry D.D. A practical approach to avoidance of methotrexate toxicity [editorial] J Rheumatol. 1995;22:1009 1012.
Chan B.S., Dawson A.H, Buckley N.A. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning? Clin Toxicol (Phila) 2017;55(2):88 96.
Ferner R.E. Adverse drug reactions in dermatology. Clin Exp Dermatol. 2015;40:105 109.
Ryan C., Amor K.T., Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010; 63 (6): 949 972.
Wallengren J. Prurigo: diagnosis and management. Am J Clin Dermatol. 2004;5 (2): 85 95.
Weigelt N., Metze D., Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol 2010: 37: 578 586.
Ferm I., Sterner M., Wallengren J. Somatic and psychiatric comorbidity in patients with chronic pruritus. Acta Derm Venereol. 2010; 90 (4): 395 400.
Lee H.G., Stull C., Yosipovitch G. Psychiatric disorders and pruritus. Clin Dermatol 2017; 35 (3): 273 280.
Qureshi A.A., BA Abate L.E., Yosipovitch G.et al. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019; 80 (3): 756 764.
Zeidler C, Yosipovitch G, Ständer S. Prurigo nodularis and its management. Dermatol Clin. 2018; 36 (3): 189 197.
Weisshaar E., Szepietowski J.C., Dalgard F.J. et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019; 99 (5): 469-506.
Siepmann D., Lotts T., Blome C. et al. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. Dermatology 2013; 227: 353 360.
Saraceno R., Chiricozzi A., Nistico S.P. et al. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J Dermatolog Treat 2010; 21: 363 366.
Wong S.S., Goh C.L. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of prurigo nodularis. Arch Dermatol 2000; 136: 807 808.
Brenninkmeijer E.E., Spuls P.I., Lindeboom R. et al. Excimer laser vs. clobetasol propionate 0,05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. Br J Dermatol. 2010; 163: 823 831.
Lee M.R., Shumack S. Prurigo nodularis: a review. Australas J Dermatol. 2005 ;46 (4): 211-218.
Maruani A., Samimi M., Lorette G. Prurigo. Presse Med. 2009;38 (7-8): 1099 1105.
Романенко И.М., Кулага В.В., Афонин С.Л. Лечение кожных и венерических болезней: Руководство для врачей: В 2 т. М.: ООО «Медицинское информационное агентство», 2006. Т.2. 888 с.
Schulz S., Metz M., Siepmann D. et al. Antipruritische Wirksamkeit einer hoch dosierten Antihistaminikatherapie. Hautarzt 2009; 60: 564 568.
Weisshaar E., Szepietowski J.C., Dalgard F.J. et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019; 99 (5): 469 506.
Мурашкин Н.Н., Глузмин М.И., Материкин А.И. Оценка эффективности антигистаминных лекарственных препаратов в комплексной терапии зудящих дерматозов с хроническим течением. Вестник дерматологии и венерологии. 2011; №4: 84 87.
Самцов А.В., Стаценко А.В., Хайрутдинов В.Р. и др. Клинический опыт примепения препарата гленцет (левоцетиризин) в терапии зудящих дерматозов. Дерматология. Приложение к журналу Consilium Medicum. 2011; №2: 13 15.
Галлямова Ю.А. Пруриго: современный взгляд на этиологию, диагностику и лечение. Лечащий врач. 2010; №6: 69.
Richards R.N. Update on intralesional steroid: focus on dermatoses. J Cutan Med Surg 2010; 14: 19 23.
Barnes P.J. Optimizing the anti inflammatory effects of corticosteroids. Eur Resp Rev 2001; 11:78:15 22.
Spring P., Gschwind I., Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol 2014; 39: 468 473.
Klejtman T., Beylot-Barry M., Joly P. et al. Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. J Eur Acad Dermatol Venereol. 2018;32:437 440.
Wiznia L.E., Callahan S.W., Cohen D.E., Orlow S.J. Rapid improvement of prurigo nodularis with cyclosporine treatment. J Am Acad Dermatol. 2018;78:1209 1211.
Hammes S., Hermann J., Roos S., Ockenfels H.M. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol 2011; 25: 799 803.
Gambichler T., Hyun J., Sommer A. et al. A randomised controlled trial on photo(chemo)therapy of subacute prurigo. Clin Exp Dermatol 2006; 31, 348 353.
Rombold S., Lobisch K., Katzer K. et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed. 2008; 24 (1): 19 23.